Yashavarddhan M H, Bohra Deepika, Rana Rashmi, Tuli Hardeep Singh, Ranjan Vivek, Rana Devinder Singh, Ganguly Nirmal Kumar
Department of Biotechnology & Research, Sir Ganga Ram Hospital, New Delhi 110060, India.
Department of Biotechnology & Research, Sir Ganga Ram Hospital, New Delhi 110060, India.
Microbiol Res. 2023 Dec;277:127504. doi: 10.1016/j.micres.2023.127504. Epub 2023 Sep 23.
The 2022 Monkeypox virus, an evolved DNA strain originating in Africa, exhibits heightened human-to-human transmissibility and potential animal transmission. Its host remains unidentified. While its initial slow transmission rate restrained global impact, 2022 saw a surge in cases, causing widespread concern in over 103 countries by September. This virus's distinctive human-to-human transmission marks a crucial shift, demanding a prompt revaluation of containment strategies. However, the host source for this shift requires urgent research attention. Regrettably, no universal preventive or curative methods have emerged for this evolved virus. Repurposed from smallpox vaccines, only some vaccinations offer a partial defense. Solely one therapeutic drug is available. The article's essence is to provide a comprehensive grasp of the virus's epidemiology, morphology, immune invasion mechanisms, and existing preventive and treatment measures. This knowledge equips researchers to devise strategies against its spread and potential public health implications.
2022年猴痘病毒是一种起源于非洲的进化DNA毒株，具有更高的人际传播性和潜在的动物传播性。其宿主仍然不明。虽然其最初缓慢的传播速度限制了全球影响，但2022年病例激增，到9月已在103个以上国家引起广泛关注。这种病毒独特的人际传播标志着一个关键转变，需要迅速重新评估防控策略。然而，这种转变的宿主来源需要紧急的研究关注。遗憾的是，针对这种进化后的病毒尚未出现通用的预防或治疗方法。从小牛痘疫苗重新利用而来的疫苗，只有部分疫苗能提供部分防护。仅有一种治疗药物可用。本文的核心是全面掌握该病毒的流行病学、形态学、免疫入侵机制以及现有的预防和治疗措施。这些知识使研究人员能够制定应对其传播及潜在公共卫生影响的策略。
